Cognition in Euthymic Patients with Bipolar Disorder: Do Not Forget to Account for Anxiety!
DOI: https://doi.org/10.2147/ndt.s457186
IF: 2.989
2024-06-05
Neuropsychiatric Disease and Treatment
Abstract:María Yoldi-Negrete, 1 Ana Fresán, 1 Laura Ivone Jiménez-Rodríguez, 2 Elsa Georgina Tirado-Durán 2 1 Clinical Epidemiology Laboratory, Clinical Research Directorate, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico City, Mexico; 2 Department of Psychology, Neuropsychology, Clinical Services Directorate, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico City, Mexico Correspondence: María Yoldi-Negrete, Email ; Purpose: Despite the high prevalence of anxiety disorders in BD and its known impact on cognitive performance, the presence and severity of anxious symptoms is not systematically evaluated in studies on cognition in BD. Our aim was to determine if attention and/or inhibition of cognitive interference in euthymic patients with type I Bipolar Disorder (BD-I) is affected by symptoms of anxiety. Patients and Methods: Eighty-seven euthymic BD-I patients were included. Patients with comorbidities other than Generalized Anxiety Disorder (GAD) or Panic Disorder (PD) were excluded. State anxiety was measured with the Brief Inventory of Anxious Responses and Situations (ISRA-B). Subjective cognitive performance was evaluated with the COBRA scale, attention with the Digit-Span Forward task and inhibition of cognitive interference was assessed with the StroopTest interference score. Multiple linear regression models were used to test if anxious symptoms were associated with attention or inhibition of cognitive interference, considering other known contributors for cognitive impairment. Results: Attention was unaffected by anxiety symptoms, but the overall regression for inhibition of cognitive interference was significant: years of schooling (β=1.12, p = 0.001), cognitive complaints (β=0.44, p = 0.008), and anxiety (β=− 0.21, p = 0.017) explained 15% of the interference score of the Stroop test (R2 = 0.15). Conclusion: Beyond residual affective symptoms, anxious symptoms seem to affect inhibition of cognitive interference. We recommend routine testing of anxiety when considering cognitive evaluations, especially when screening for cognitive deficits. Keywords: anxiety, attention, digit span forward, cognitive interference, Stroop effect, bipolar-I disorder, comorbid Bipolar Disorder (BD) is a chronic, highly disabling condition, characterized by severe mood instability. This disorder is accompanied by cognitive deficits, which vary in severity, and are present in the majority of patients, even before illness onset and despite being in euthymia. 1–3 The importance of recognizing their presence lies in their link to functional and other well-being outcomes: cognitive variables are associated with functioning scores as evidenced by transversal as well as longitudinal studies. 4–9 Several factors are related to these deficits, likely in a two-direction relationship, and are therefore systematically evaluated when studying cognitive symptoms in this population. Such is the case of age, illness duration, number and type of affective episodes and history of psychotic symptoms as all have been linked to differential cognitive performance. 10–13 Furthermore, depressive and manic symptoms have such high correlation with these deficits that studies on cognition must not only state the affective state of participants but also report the severity of residual symptoms, as important differences have been documented between performance in euthymia and performance in active episodes. 12,14 Also, as comorbid substance use disorder also affects cognitive performance and is so common in BD, participants with active substance use are systematically excluded from studies on cognition in BD (for example, see exclusion criteria of). 1,9,12,14,15 On the other hand, anxious symptoms, whether part of a comorbid anxiety disorder or independent, are highly prevalent in persons with BD and are risk factors of various poor outcome measures, such as relapse, hospitalizations, suicidal behavior, functioning and lower quality of life. 16–23 Also, anxiety, as a general construct, is related to diminished performance on cognitive tasks, particularly with attentional control aspects of the central executive. 24 Thus, it would be expected that the presence of anxious symptoms (whether or not sufficient to fulfill criteria for a comorbid anxiety disorder) would worsen cognitive performance of patients with BD. A few studies have addressed this question: Wu et al compared performance on memory, attention, psychomotor speed, and frontal executive function between euthymic patients with type II BD (BD-II) with and without comorbid anxiety, and non-bipolar controls. 25 Only participants from the BD g -Abstract Truncated-
psychiatry,clinical neurology